Lirentelimab
Based on 1 Customer Validation
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.91%
- CAS. Nr.: 2283348-97-8
- Molecular Weight:144.31 kDa
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
Siglec-8
In Vitro
Monovalent Lirentelimab fragment antigen-binding (fab) binds to recombinant SIGLEC8 extracellular domain (ECD) is determined to be 464 pM[1]. Lirentelimab shows high affinity to SIGLEC8 in vitro, to SIGLEC8 expressed on eosinophils, and to NK cells via its Fc region in human blood[1]. Lirentelimab (1 µg/mL) selectively binds to eosinophils in human peripheral blood, and eosinophils and mast cells from human lung tissue[1]. Lirentelimab (0.0001-100 μg/mL; 30 min) induces apoptosis of IL-5-activated eosinophils[1]. Lirentelimab (30 min) shows potent antibody-dependent cell-mediated cytotoxicity (ADCC) Activity on human eosinophils with an EC50 value of 1.9 ng/mL to eosinophils in peripheral blood leukocytes (PBL) preparations from healthy donors[1]. Lirentelimab reduces eosinophil numbers in ex vivo human tissue[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Eosinophils
-
Concentration:10 μg/mL-1 pg/mL
-
Incubation Time:30 min
-
Result:Dose-dependently induced apoptosis of IL-5-activated (50 ng/mL) eosinophils.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Humanized mice (NSG-SGM3) engrafts with human thymus, liver, and HSC[1]
-
Dosage:100 μg
-
Administration:Intravenous injection; 100 μg, once
-
Result:Completely prevented passive systemic anaphylaxis (PSA) as shown by a lack of change in rectal temperature and symptom scores in mice.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Siglec-8 Protein, Human (HEK293, His, HY-P71313) can bind Lirentelimab. The EC50 for this effect is 2.468 ng/mL.
Chemical Information
-
CAS. Nr. 2283348-97-8
-
Appearance Liquid
-
Molecular Weight 144.31 kDa
-
Color Colorless to light yellow
-
SMILES
[Lirentelimab]
-
Synonyms
AK002; Antolimab
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Youngblood BA, et al. AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice. Int Arch Allergy Immunol. 2019;180(2):91-102. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)